Articles tagged with Multiple Sclerosis
A new study published in Neurology found no link between dietary intake of minerals like zinc, iron, and other minerals with the development of multiple sclerosis. The study involved over 80,000 female nurses and found no association between mineral intake and MS risk.
Researchers optimized a 20-nucleotide DNA aptamer to improve its binding properties to myelin, a promising lead molecule for multiple sclerosis therapy. The study provides the first evidence of cross-reactivity with human brain cells.
Researchers found that brain stem cells from primary progressive MS patients act and look older than normal cells, affecting myelin production. Blocking a specific protein may improve oligodendrocyte growth and offer new treatment options.
A new study attributes the link between earlier puberty and multiple sclerosis (MS) to body mass index (BMI), finding that increased BMI is also linked to a greater risk of MS. Researchers analyzed genetic data from over 329,000 women and found that people with an earlier age of puberty were more likely to develop MS.
A UBC study found that beta interferon treatment for multiple sclerosis patients is associated with a 32% lower mortality risk compared to those who did not take the drug. The study followed nearly 6,000 people with MS in Canada and France over two decades.
Virginia Tech professor Webster Santos has received a grant to discover drugs that inhibit a small molecule transporter, which modulates the immune system and could treat multiple sclerosis. The collaboration aims to develop SPNS2 inhibitors for treating MS and metastatic cancers.
A new study found that non-contrast MRI is just as effective as contrast-enhanced MRI for monitoring disease progression in MS patients. The study used image subtraction techniques to detect newly occurring lesions with high sensitivity.
A new study found that the risk of relapse in multiple sclerosis (MS) is lower during and after pregnancy than previously thought. Women with MS can have children without an increased risk of relapses, according to a preliminary study published by the American Academy of Neurology.
Researchers examine experiences of families with pediatric onset MS, finding complex diagnostic odyssey and high emotional toll. Disease-modifying treatments improve outcomes, but long-term emotional support needed for patients' families.
A study of 135 people with multiple sclerosis found that drinking around 290 calories per day of soda or other sugar-sweetened beverages linked to more severe symptoms and a higher level of disability. Those who seldom consumed these beverages had less severe symptoms, highlighting the potential negative impact on MS progression.
Researchers found that high flavonoid cocoa powder improved fatigue in people with multiple sclerosis by reducing mental and physical fatigue. Participants who drank the high flavonoid version showed a moderate effect on fatigability and improvements in pain symptoms, while those drinking low flavonoid cocoa saw no significant benefits.
Researchers at the Advanced Science Research Center have identified a mechanism by which metabolites inhibit epigenetic changes in brain-homing immune cells, which play a key role in multiple sclerosis. The discovery could lead to more specific and effective MS therapies.
Researchers will examine how individuals with MS process outcomes of their actions during cooperative interactions, aiming to maximize their competence in social interactions. The study will focus on the impact of delayed reciprocation vs immediate reciprocation on outcome processing in individuals with MS.
A new study from the University of British Columbia found that neighbourhood income and education level are associated with an increased risk of disability progression in patients with multiple sclerosis. The research suggests that modifiable lifestyle factors, such as diet and exercise, could be involved in this relationship.
Dr. Ekaterina Dobryakova, a researcher at Kessler Foundation, has been honored with the International Neuropsychological Society's Early Career Award for her work on traumatic brain injury and multiple sclerosis. Her research focuses on noninvasive interventions to address cognitive deficits caused by these conditions.
Researchers have developed a new compound that shows promise in treating multiple sclerosis by reducing inflammation and promoting neuroprotection and remyelination. The compound, based on chloroindazole, has been found to be effective in improving primary symptoms in a mouse model of the disease.
A new study found that multiple sclerosis patients with food allergies experienced a higher rate of disease activity and increased likelihood of new lesions compared to those without food allergies. The association highlights the potential role of the gut in MS immune dysregulation.
Researchers created a high-resolution map of the brain's immune system, showing that all microglia have the same core signature but adapt differently depending on their function. This discovery is significant for understanding brain diseases like multiple sclerosis and Alzheimer's.
A team of scientists discovered that Blimp1 prevents the loss of identity in regulatory T cells, a type of immune cell that controls inflammation. This finding has implications for therapies against inflammatory autoimmune diseases such as multiple sclerosis and arthritis.
A recent study published in Nature Communications identifies Satb1 as a protein regulator that induces the pathogenic properties of Th17 cells, leading to multiple sclerosis and other inflammatory autoimmune disorders. By targeting Satb1 gene expression in Th17 cells, novel treatments may be developed to alleviate or eliminate disease ...
Researchers at University of Freiburg discover new immune cells that promote multiple sclerosis development, creating an immune cell atlas for the brain. Chronic activation of these cells may explain why the brain is chronically attacked in MS patients.
Researchers found that Medicare patients with multiple sclerosis spend $6,894 a year out of pocket for treatment. This is attributed to the lack of incentives for companies not to raise prices, leading to restrictive policies and high coinsurance cost-sharing models.
A team of researchers has identified a mechanism that contributes to the degeneration of axons in multiple sclerosis, leading to permanent neurological deficits. They found that minuscule ruptures in the cell membrane allow calcium ions to enter the neuron, disrupting its balance and ultimately killing it.
A study published in Nature found that people with multiple sclerosis have different types of oligodendrocytes than healthy individuals, which may explain why their myelin repair process does not work as well. This discovery could lead to the development of new treatments for progressive MS.
Researchers found that older cells in MS patients can reform myelin, but new oligodendrocyte generation is severely limited. This suggests treating MS aggressively at an early stage is crucial to prevent further damage.
A team from Charité has identified the Chi3l3 protein as a key player in the body's innate ability to repair damaged myelin sheaths in multiple sclerosis. By understanding this molecular signal, researchers aim to develop new drugs that can restore electrical insulation around nerve cells.
A new systematic approach has identified environmental factors that boost neurological inflammation, including an herbicide banned in Europe. Researchers found that linuron and another compound increase activity of a gene associated with inflammation.
International study finds MS treatments can delay secondary progressive stage of the disease by five years or more, improving quality of life. Early treatment is essential to prevent worsening disability and irreversible loss of function.
Researchers at the University of Chicago Medical Center have found a promising treatment for multiple sclerosis, a disabling immune-mediated disease that damages nerve fibers. Sephin1, a small molecule, may delay harm to nerve cells by protecting oligodendrocytes and reducing inflammation.
Gut immune cells, specifically plasma cells producing Immunoglobulin A antibodies, migrate to the central nervous system and produce an anti-inflammatory effect during MS flare-ups. Increasing these cells blocks inflammation entirely in a preclinical model of the disease.
The proposal calls for pharmaceutical companies to collect post-marketing data in all minority groups, classifying responsiveness based on ethnicity. Package labelling should include efficacy data from minority populations.
Research published in the Journal of Neurology & Psychiatry found that food allergies are associated with a higher rate of cumulative disease bouts and active disease in multiple sclerosis patients. The study analyzed data from 1349 adults and found that food allergy was linked to a 27% higher rate of disease flare-ups.
A University at Buffalo team discovered that activation of PRRX1 induces pathological quiescence, rendering adult stem cells incapable of producing myelin-forming oligodendrocytes. This finding presents a novel approach to developing treatments for multiple sclerosis and other inflammatory diseases by blocking pathological quiescence.
Researchers at Karolinska Institutet discovered that oligodendrocytes, cells responsible for myelin production, may play a significant role in MS development. This finding could lead to new therapies targeting areas beyond the immune system.
A recent study published in Nature Immunology found that B cell accumulation triggers nervous system damage in MS patients. The presence of myeloid-derived suppressor cells (MDSCs) regulates the number of B cells, and their absence leads to inflammation and tissue damage.
Researchers found that the thymus, a small organ near the heart, maintains its output of T cells during pregnancy, which is essential for protecting against infection while tolerating the fetus. The study's findings may have implications for understanding autoimmune diseases like multiple sclerosis.
Researchers are conducting a randomized controlled trial to investigate the effects of treadmill walking exercise training on learning and memory performance, hippocampal volume, and resting-state functional connectivity in people with Multiple Sclerosis (MS). The study aims to determine if aerobic exercise can improve cognitive defici...
A new study finds that pelvic floor muscle exercises can significantly improve overactive bladder symptoms in patients with neurogenic and non-neurogenic conditions. The study suggests that PFM training activates the frontal cortex of the brain, leading to improved conscious control of bladder function.
A Yale-led team has identified four new genetic variants that directly damage gene sequences, accounting for an additional 5% of MS disease risk. The findings contradict previous theories on the role of common genetic variants in MS, providing promising new avenues for research and study.
A new conceptual framework proposes examining exercise effects on brain connectivity, structure, and molecular mechanisms in multiple sclerosis. This systematic approach may lead to new strategies for rehabilitative care and treatment.
Researchers found structural changes in myelin sheaths triggered by environmental factors can lead to autoimmune attacks that cause MS. The study suggests even minor changes in local conditions may precipitate the disease.
A recent study by the MAGNIMS Study Group provides new insights into the involvement of the hippocampus in multiple sclerosis, a neurodegenerative disease that affects cognition. The research suggests that modifying the hippocampus through aerobic exercise and memory retraining may be effective in improving cognitive outcomes for MS pa...
Scientists have developed an antibody that blocks the inflammatory and oxidative activity of fibrin, a blood protein that contributes to neurodegeneration in the brain. The treatment has shown promise in reducing inflammation and neurodegeneration in both mouse models of multiple sclerosis and Alzheimer's disease.
Researchers discovered that herpesvirus 6 infection before inducing EAE significantly accelerated the disease's progression in marmosets. This finding supports the hypothesis that viral infections can increase susceptibility to autoimmunity by triggering a heightened immune state.
A systematic review and meta-analysis of 17 clinical trials found that medical marijuana reduced subjective patient assessments of spasticity, pain, and bladder dysfunction in patients with multiple sclerosis. However, the therapy may carry a higher risk of adverse events compared to placebo.
New findings suggest that the immune system's response to a protein called GDP-L-fucose synthase, found in both human cells and bacteria, may play a key role in multiple sclerosis. The protein is believed to activate T cells in the intestine, leading to an inflammatory cascade that damages the protective coating around nerve cells.
Dr. John DeLuca is recognized for his outstanding record of professional service and contributions to the field of medical rehabilitation. He leads rehabilitation research and training at Kessler Foundation, improving rehabilitation outcomes for individuals with disabilities.
A study by Brigham and Women's Hospital researchers found that people's social networks have a strong association with their reported neurological disability. The team developed a social network assessment tool, which found that unhealthy habits of those around an individual can significantly impact their health outcomes.
A recent study by MS researchers found that older individuals with multiple sclerosis report lower levels of depression and higher quality of life than their younger counterparts. This trend is consistent with the general population, where well-being improves with age.
A pilot study by Kessler Foundation researchers found improvements in processing speed training for individuals with multiple sclerosis, enhancing neuropsychological tests and daily life performance. The study showed significant gains in processing speed, new learning, memory, and activities of daily life.
Researchers at UVA have discovered that lymphatic vessels in the brain carry messages from the brain to the immune system, triggering MS symptoms. Blocking these messages may offer a new way to treat the condition, but more research is needed to understand their role and potential therapeutic targets.
A four-year grant funds a collaborative study with 11 centers worldwide to assess the efficacy of cognitive rehabilitation and aerobic exercise on cognitive function in people with progressive MS. Researchers aim to demonstrate improved brain activity in regions responsible for memory, learning, and executive functioning after treatment.
Researchers discovered that B cells activate specific T cells causing inflammation and nerve cell damage in MS patients. This finding explains how novel drugs like Rituximab and Ocrelizumab inhibit inflammation.
A phase 2 trial conducted by Cleveland Clinic shows that ibudilast decreased progression of brain atrophy in progressive MS patients by 48 percent versus placebo. The study also demonstrated the utility of advanced imaging in clinical trials to measure the impact of therapies on brain health.
A clinical trial of over 250 participants with progressive multiple sclerosis found that ibudilast slowed down brain shrinkage compared to a placebo. The study showed a difference of approximately 2.5 milliliters of brain tissue between the two groups, but it is unclear if this translates to improved symptoms or function.
Researchers have discovered a novel subtype of multiple sclerosis, called myelocortical MS (MCMS), which features neuronal loss but no demyelination in the brain's white matter. This new subtype is indistinguishable from traditional MS on MRI and has reduced neuronal density and cortical thickness.
Dr. Silvana Costa receives a National MS Society grant to investigate the effect of visual, cognitive, and motor deficits on information processing speed in individuals with multiple sclerosis. The four-year study will utilize neuropsychological evaluations and eye-tracking technology.
Researchers at Case Western Reserve University School of Medicine have identified dozens of drug candidates that share a common mechanism to repair damaged brain cells in multiple sclerosis. These new targets and potent early-stage drug candidates could lead to regenerative medicines for the debilitating disease.
Researchers identified a molecular key, P2X4 receptor, that delays Multiple Sclerosis (MS) progression by reducing chronic inflammation and promoting repair responses in the nervous tissue. The study found that activating this receptor improves symptoms during the disease's chronic phase.
A collaborative study funded by NIH aims to assess the effects of treadmill walking exercise on cognitive processing speed, brain volume, and functional connectivity in individuals with MS. Researchers hope to develop exercise training guidelines to improve cognition and brain health in people with MS.